Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease ...

Novo Nordisk shares were climbing Monday after the Food and Drug Administration approved the popular weight-loss drug Wegovy ...

The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with ...

By Jacob Gronholt-Pedersen COPENHAGEN, DENMARK (Reuters) -Shares in Novo Nordisk rose on Monday, after it got U.S. approval ...

The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a form of liver disease.

Novo Nordisk A/S shares advanced after the drugmaker’s blockbuster weight-loss drug Wegovy received US approval to treat a ...

FDA approves Novo Nordisk's Wegovy for MASH with liver fibrosis, supported by ESSENCE trial data as the company projects ...

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

Copenhagen-listed shares in pharmaceuticals giant Novo Nordisk rose nearly 4% on Monday morning, after the company announced that its blockbuster wei ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Echosens, the leader in non-invasive liver diagnostics, and Novo Nordisk are strengthening their aligned efforts to combat steatotic liver disease, following the U.S. Food and Drug Administration's ...